disease 1,386 words KG: ent-dise-3216eca2
Contents

Mixed Dementia

Disease Info
Schneider et al. (2007)In the Rush Memory and Aging Project, among community-dwelling older persons with dementia, only 30% had pure AD pathology; 38% had AD with cerebral infarcts, and 12% had AD with Lewy body disease
The 90+ StudyIn the oldest-old, multiple pathological diagnoses occurred in 45% of those with dementia versus 14% without dementia
ROSMAP CohortAmong persons clinically diagnosed with probable AD, nearly 90% had pathologically confirmed ADNC, but almost half had mixed pathologies. Pure pathologic AD accounted for less than 10% of cases
Metabolic reserve reductionCerebrovascular disease reduces the brain's metabolic reserve, lowering the threshold at which amyloid and tau] burdens produce clinical symptoms
Cerebral amyloid angiopathyPresent in ~90% of AD cases, compromising the blood-brain barrier
Shared risk factorsHypertension, diabetes, and dyslipidemia operate on both pathways
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (18)

RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
APOE-TREM2 Interaction Modulation
Score: 0.74
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
APOE Isoform Conversion Therapy
Score: 0.72
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58

Related Analyses (5)

Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed

Related Experiments (4)

Vascular Contributions to Alzheimer Disease and Mixed Pathol
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.